[PDF]NO NO NO NO NO NO NO - Rackcdn.comhttps://75c17d9f6eecafb09b78-695e1a25d6559f5c6a6714b54be309d0.ssl.cf3.rackcd...
0 downloads
381 Views
45KB Size
UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2015 OS PC DESPATCHED ON 24TH MARCH 2015 HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A24; B7, B8; Cw7,-; DR4, DR17; DQ2, DQ8 Summary of Results PBL/T-Cells
B-Cells
Total tested Positive Negative NT/Equivocal % Positive % Negative
29 0 29 4 0.0% 100.0%
29 3 26 4 10.3% 89.7%
29 1 28 4 3.4% 96.6%
29 1 28 4 3.4% 96.6%
22 0 22 2 0.0% 100.0%
22 2 20 2 9.1% 90.9%
22 5 17 2 22.7% 77.3%
22 7 15 2 31.8% 68.2%
Consensus
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Not Assessed
DQ1
A9, DR15
DQ3
A2, B17
DQ1
A9, DR15
DQ3
A2, B17
Serum 1
Without DTT Serum 2 Serum 3
Serum 4
Negative
Negative
Positive
Positive
Negative
Positive
Positive
Positive
Negative Negative Negative Negative
Negative Negative Negative Negative
Negative Negative Negative Negative
Positive Negative Weak Positive Negative
Negative Negative Negative Negative Negative NT Negative Negative
Negative Negative Negative Negative Negative NT Negative Negative
Negative Negative Negative Negative Negative NT Positive Negative
Positive Negative Negative Negative Negative NT Negative Negative
NT
NT
NT
NT
Negative Negative Negative Negative Negative Negative Negative Negative Negative
Positive Negative Negative Negative Negative Negative Negative Negative Negative
Positive Negative Negative Negative Negative Positive Negative Negative Negative
Positive Negative Negative Negative Negative Positive Negative Negative Negative
HLA Antibody Specificity (Defined By CDC)
Lab No. 112 116 119 120 128 139 143 147 154 157 159 174 181 189 190 193 194 195 197 209 216 223 229 232 238 245 252 259 260 262 293 294 297
PBL/T Cell
B Cell
Assessment
Assessment
YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES
NO NO
NO YES NO YES
NO YES YES YES YES
NO YES YES YES YES YES YES YES YES
NO YES NO
NO YES YES YES YES YES YES YES YES YES
Serum 1
Without DTT Serum 2 Serum 3
Serum 4
Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative NT Negative Negative Negative Negative Negative NT NT Negative Negative Negative Negative NT Negative Negative Negative Negative Negative Negative Negative Negative Negative
Negative Negative Positive Negative Negative Positive Negative Negative Negative Negative Negative NT Negative Negative Negative Negative Negative NT NT Negative Negative Negative Negative NT Positive Negative Negative Negative Negative Negative Negative Negative Negative
Negative Negative Positive Negative Negative Negative Negative Negative Negative Negative Negative NT Negative Negative Negative Negative Negative NT NT Negative Negative Negative Negative NT Negative Negative Negative Negative Negative Negative Negative Negative Negative
Negative Positive Negative Negative Negative Negative Negative Negative Negative Negative Negative NT Negative Negative Negative Negative Negative NT NT Negative Negative Negative Negative NT Negative Negative Negative Negative Negative Negative Negative Negative Negative
Poor cell viability
No results returned Poor T cell viability
Poor B cell viability Poor cell viability
Page 1 of 4 UK NEQAS for H&I is provided from the Welsh Blood Service which is a division of Velindre NHS Trust © Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I
UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2015 OS PC DESPATCHED ON 24TH MARCH 2015
Lab No. 112 116 119 120 128 139 143 147 154 157 159 174 181 189 190 193 194 195 197 209 216 223 229 232 238 245 252 259 260 262 293 294 297
Serum 1 reaction strength
PBL/T-cell without DTT Serum 2 Serum 3 reaction reaction strength strength
Serum 4 reaction strength
-1 1 1 1 1 1 2 1 1
-2 1 6 1 1 4 2 1 1
-1 2 1 1 1 1 2 1 1
-1 1 4 1 1 1 2 1 1
1 NT 1 1 2% 1 1
1 NT 1 1 2% 1 1
1 NT 1 1 2% 1 1
1 NT 1 1 2% 1 1
NT
NT
NT
NT
2 1
2 1
2 1
2 1
Serum 1 reaction strength
B-cell without DTT Serum 2 Serum 3 reaction reaction strength strength
Serum 4 reaction strength
Cell viability % PBL T-cells B-cells 90 90 85
1
1
4
4
1
4
6
6
1 1
1 1
1 1
8 1
1
1
1
1
1 1 5% 1 1
1 1 5% 1 1
2 1 20% 1 1
4 1 20% 1 1
80 80
100
NT 1 1 1
0 1
NT 2 1 1
0 1
NT 1 1 1
0 1
NT 1 1 1
0 1
Moderate
85 90
100 80
100
100
80 90 100 95 100 100
80 100 95 100 100
90 98 99 98
85 88 95 95 98
50 95
70 95
90
60
80 100
60 100 30 90 80 100 60 95 80
80 NT
1 1 1
2 1
NT
4 1 1
2 1
NT
6 1 1
NT
6 1 1
90 20 90 100 40 90
8
8
100
2 1
2 1
80
90 90 100 70 95 80
Page 2 of 4 UK NEQAS for H&I is provided from the Welsh Blood Service which is a division of Velindre NHS Trust © Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I
UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2015 OS PC DESPATCHED ON 24TH MARCH 2015 HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A24; B7, B8; Cw7,-; DR4, DR17; DQ2, DQ8 Summary of Results PBL/T-Cells
B-Cells
Total tested Positive Negative NT/Equivocal % Positive % Negative
23 0 23 4 0.0% 100.0%
23 3 20 4 13.0% 87.0%
23 0 23 4 0.0% 100.0%
23 0 23 4 0.0% 100.0%
20 0 20 2 0.0% 100.0%
20 2 18 2 10.0% 90.0%
20 5 15 2 25.0% 75.0%
20 3 17 2 15.0% 85.0%
Consensus
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
DQ1
A9, DR15
DQ3
A2, B17
DQ1
A9, DR15
DQ3
A2, B17
Serum 1
With DTT Serum 2 Serum 3
Serum 4
Negative Negative Negative NT Negative Negative
Negative Positive Negative NT Negative Negative
Positive Positive Negative NT Negative Negative
Positive Positive Negative NT Negative Negative
Negative Negative Negative Negative Negative NT Negative Negative
Negative Negative Negative Negative Negative NT Negative Negative
Negative Negative Negative Negative Negative NT Positive Negative
Negative Negative Negative Negative Negative NT Negative Negative
Negative Negative Negative Negative Negative Negative Negative Negative
Positive Negative Negative Negative Negative Negative Negative Negative
Positive Negative Negative Negative Positive Negative Negative Negative
Positive Negative Negative Negative Negative Negative Negative Negative
HLA Antibody Specificity (Defined By CDC)
Lab No. 112 116 119 120 139 147 154 157 159 174 181 189 190 193 194 195 197 209 216 229 238 245 252 260 262 293 294 297
PBL/T Cell
B Cell
Assessment
Assessment
YES YES YES YES YES YES YES NO YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES
NO NO
NO YES YES YES YES YES YES NO YES YES YES YES YES YES YES YES
NO NO YES YES YES YES YES YES YES YES
Serum 1
With DTT Serum 2 Serum 3
Serum 4
Negative Negative Negative Negative Negative Negative NT
Negative Negative Positive Negative Positive Negative NT
Negative Negative Negative Negative Negative Negative NT
Negative Negative Negative Negative Negative Negative NT
Negative NT Negative Negative Negative Negative Negative NT NT Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative
Negative NT Negative Negative Negative Negative Negative NT NT Negative Negative Negative Positive Negative Negative Negative Negative Negative Negative Negative
Negative NT Negative Negative Negative Negative Negative NT NT Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative
Negative NT Negative Negative Negative Negative Negative NT NT Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative
Low cell count
Poor cell viability
Page 3 of 4 UK NEQAS for H&I is provided from the Welsh Blood Service which is a division of Velindre NHS Trust © Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I
No results returned Poor T cell viability
UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2015 OS PC DESPATCHED ON 24TH MARCH 2015
Lab No. 112 116 119 120 139 147 154 157 159 174 181 189 190 193 194 195 197 209 216 229 238 245 252 260 262 293 294 297
Serum 1 reaction strength -1 1 1 1 1 1 NT
PBL/T-cell with DTT Serum 2 Serum 3 reaction reaction strength strength -2 1 2 1 4 1 NT
-1 1 1 1 1 1 NT
Serum 4 reaction strength -1 1 1 1 1 1 NT
Serum 1 reaction strength
B-cell with DTT Serum 2 Serum 3 reaction reaction strength strength
Serum 4 reaction strength
Cell viability % PBL T-cells B-cells 90 90 85
1 1 1 NT
1 4 1 NT
4 6 1 NT
4 6 1 NT
80
100 1 NT 1 1 2% 1 1
1 NT 1 1 2% 1 1
1 NT 1 1 2% 1 1
1 NT 1 1 2% 1 1
NT
NT
NT
NT
2
2
2
2
1 1 1
2 1 1
1 1 1
1 1 1
1
1
1
1
1 1 10% 1 1
1 1 10% 1 1
1 1 10% 1 1
2 1 10% 1 1
1 1 1
2 1 1
0 1
0 1
0 1
0 1
2 1
100
Moderate
80
4 1 1
80 90 90 100 40
2 1 1
100
6 0 1
85 90
2 1
2 1
80
100 80 100 95 100 100
100 80 100 95 100 100
90 98 99 98
85 88 95 95 98
50 95
70 95
80 100
60 100 30 80 100 60 95 80
90 100 70 95 80
Page 4 of 4 UK NEQAS for H&I is provided from the Welsh Blood Service which is a division of Velindre NHS Trust © Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I
